The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
 
Richard D. Kim
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Sanofi
Research Funding - Bayer; Novartis
 
Shannon McDonough
No Relationships to Disclose
 
Anthony B. El-Khoueiry
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - Exelixis; Polaris
 
Katherine Guthrie
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
Speakers' Bureau - Genomic Health